Dr. Sayare was appointed to the company’s board of directors in April 2010 and served as chairman of the board since January 2018. Most recently, he served as chairman and chief executive officer of ImmunoGen, a publicly traded biotechnology company engaged in the research and development of antibody-based cancer therapeutics. During his tenure with ImmunoGen, Dr. Sayare was responsible for leading a successful IPO and raising over $300 million in venture capital and public equity financing for the company. Dr. Sayare also served as president of the 95%-owned ImmunoGen subsidiary, Apoptosis Technology, where he was responsible for managing operations for the organization. Prior to joining ImmunoGen, Dr. Sayare served as vice president, development at Xenogen, Inc., a biotechnology company specializing in monoclonal antibody-based diagnostic systems for cancer. In this role he oversaw all research and development, corporate development and investor relations responsibilities for the company. Dr. Sayare earned his Ph.D. in biochemistry from the Temple University School of Medicine and his undergraduate degree from Ursinus College.